Royalty Report: Drugs, Vaccine, Drug Discovery – Collection: 305251


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 18


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 18

Primary Industries

  • Drugs
  • Vaccine
  • Drug Discovery
  • Cancer
  • Viral Infection
  • Respiratory
  • HIV / AIDs
  • Delivery
  • Therapeutic
  • Proteins
  • HPV
  • Immune
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 305251

License Grant
With this asset purchase agreement Buyer acquired an exclusive license with respect to Premas’ vaccine platform.
License Property
The sole asset consists of an exclusive license with respect to Premas’ vaccine platform for the development of a vaccine against COVID-19 and other coronavirus infections.

Premas vaccine platform is certain patent applications, know-how and other proprietary information related to a vaccine platform that involves genetically engineered and modified yeast, Saccharomyces cerevisiae, which along with certain proprietary expression vectors and optimized genes developed to be used with the above strain, and, has been shown to be useful in the expression of more than thirty type 1 endoplasmic reticulum associated proteins.

Field of Use
The field of use is infection and disease.  The Field of the Premas’ vaccine platform shall encompass the vaccination against, and prevention, treatment, and management, of COVID-2019 and any mutations thereof, and any other novel corona virus and any mutations thereof.  COVID-19, new Corona Virus has three major antigens or immunogens which are type 1 endoplasmic reticulum associated proteins, primarily the “S” spike protein, “E” Envelope protein and “M”, membrane protein.

IPSCIO Record ID: 298360

License Grant
This agreement is to form a joint venture entity to cooperate and use commercially reasonable efforts to exchange information and resources that will lead to the development of Licensed Products.
License Property
The Licensee has rights to VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Licensee from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH).

Licensor is is a clinical-stage biopharmaceutical company with expertise in the pre-clinical and clinical development of pharmaceutical products.

Licensed Product means products and services that are made, made for, used, imported, offered for sale or sold by Company or its Affiliates or sublicensees in the field.

Field of Use
License is  for the development of vaccine prospects for Coronavirus (COVID-19) based upon VaxCelerate, a self-assembling vaccine platform.

•VaxCelerate offers two unique elements to combat the Coronavirus – one fixed immune adjuvant and one variable immune targeting and offers several potential advantages over other compounds in combination therapy.

The vaccine focuses on both DNA and internal/external mutated proteins providing the immune system with more potential targets to attack.

Field shall mean all products and processes or uses developed hereunder, whether or not related to the Patent Rights, for the prevention, interception or treatment of COVID-19 and other related corona viruses, or otherwise.

IPSCIO Record ID: 340468

License Grant
Licensor will grant to Licensee an exclusive (even as to Licensor except as necessary for Licensor to perform its obligation hereunder and under the Development Plan) , worldwide license including the right to sublicense through multiple tiers of sublicensees under the Licensed IP, to discover, develop, make, have made, use, sell, have sold, offer for sale, market, export, import and otherwise commercialize and exploit Products in the Field in the Territory.

Licensor will grant to Licensee an exclusive, worldwide license under Licensors rights in certain patents and related intellectual property, or the License, in which Licensee will receive certain rights relating to Licensor’s proprietary oral delivery technology to further develop, manufacture and commercialize oral vaccines for COVID-19 and other novel coronaviruses based on proprietary vaccine technology involving a triple antigen virus like particle, or the Product.

License Property
Product shall mean any oral vaccines for COVID-19 and other novel coronaviruses utilizing the Licensee Technology for use in the Field that is integrated with or delivered by way of the Licensed IP under this Agreement.

Licensed IP means Patent Rights, Know-How and Information related to Licensor’s proprietary PODTM oral delivery technology involving a triple antigen virus like particle, or the Product.

The oral COVID-19 vaccine being developed promoted both systemic immunity through Immunoglobulin G (IgG), the most common antibody in blood and bodily fluids that protects against viral infections, and Immunoglobulin A (IgA).

Field of Use
Field shall encompass the vaccination against, and prevention, treatment, and management, of COVID-19 and any mutations thereof, and any other novel coronavirus and any mutations thereof after the Effective Date, and any symptoms related to the foregoing

Licensee is focused on the development of novel oral COVID-19 vaccines based on Licensor’s proprietary PODTM oral delivery technology as well as novel vaccine technology that was previously assigned to Licensee.

IPSCIO Record ID: 305790

License Grant
Under this license, Licensee received an exclusive, worldwide, royalty-bearing, sublicenseable license under Licensor’s patents and know-how relating to cell-free expression of proteins to (i) research, develop, use, sell, offer for sale, export, import and otherwise exploit specified vaccine compositions, such rights being sublicensable, for the treatment or prophylaxis of infectious diseases, excluding cancer vaccines, and (ii) manufacture, or have manufactured by an approved contract manufacturing organization, such vaccine compositions from extracts supplied by Licensor pursuant to the Licensor Supply Agreement.  Licensee is obligated to use commercially reasonable efforts to develop, obtain regulatory approval for and commercialize the vaccine compositions.
License Property
The vaccine compositions used the Licensors proprietary cell-free protein expression technology, known as XpressCF which utilizes extracts derived from strains of E. Coli.

Licensor is a clinical stage, publicly-traded drug discovery, development and manufacturing company using precise protein engineering and rational design (enabled by Licensors proprietary XpressCF platform technology) to advance next-generation oncology therapeutics.

The primary invention underpinning the XpressCF platform was the creation of engineered E.coli-derived proprietary extracts containing fully functional oxidative phosphorylation machinery in inverted membrane vesicles and orthogonal tRNA capable of catalyzing nnAA incorporation. This innovation enables the Extract to regenerate high energy phosphates required for protein translation and nnAA incorporation, reducing production cost and permitting the use of industrial sized reaction vessels and longer manufacturing run times than previously thought possible. The XpressCF system routinely produces g/L of complex proteins in 8-10 hours and scales linearly from bench to large-scale GMP production. The protein of interest is produced at high yield and the absence of cellular debris combine to simplify downstream purification, further enhancing production efficiency.

Field of Use
The XpressCF platform is used in the field of vaccines to address infectious diseases in both human and animal use.

XpressCFâ„¢, an industrialized cell-free protein synthesis platform, for the vaccine field allowing (1) site-specific conjugation; (2) production of complex antigens in more optimal conformation; and (3) speed, flexibility and scalability of the discovery engine.

The XpressCF platform overcomes these significant limitations by separating the precise cellular machinery required for transcription, translation, and energy production into an E.coli-derived mixture, or Extract capable of continuous oxidative phosphorylation.

Licensee is a next-generation vaccine company whose cell-free protein synthesis platform enables the design and production of optimized protein carriers and antigens, the critical building blocks of vaccines.

IPSCIO Record ID: 297935

License Grant
Licensee has exclusively licensed the Xpress CF technology for the vaccine field from Licensor, who has industrialized and scaled the platform at its GMP facility.

Under a license from Licensor, Licensee has right to use the XpressCF® and XpressCF+™ platforms to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases.

License Property
Licensor retains the right to discover and develop vaccines for treatment or prophylaxis of any disease not caused by an infectious pathogen, including cancer.

XpressCF® – integrated cell-free protein synthesis platform

XpressCF+â„¢ –  site-specific conjugation platform

Both of these platforms allow to rapidly and precisely create optimally designed, next-generation protein therapeutics candidates.

The platform represents a major advancement over conventional conjugate vaccine production methods, by enabling precise and consistent conjugation of antigens to site-specific locations on a protein carrier that do not impede T-cell help resulting in higher-potency conjugates.

Field of Use
XpressCF® and XpressCF+â„¢ technology platforms  led to the discovery of STRO-001 and STRO-002, Licensor’s first two internally-developed ADCs. STRO-001 is a CD74-targeting ADC currently being investigated in a Phase I clinical trial of patients with advanced B-cell malignancies, including multiple myeloma and non-Hodgkin lymphoma.

IPSCIO Record ID: 379884

License Grant
Licensor, a hospital/medical center, hereby grants the following to Licensee during the Term, solely within the Territory and solely in the Field of Use

An exclusive license under the Patents to (a) Develop, make, lease, sell, license, or otherwise distribute Products; and (b) Practice the Processes solely as necessary for the exercise of the foregoing rights.

A non-exclusive limited license to use and copy the Technology internally solely as necessary for the use or practice of the Patents. Hospital will deliver a copy of the Technology to Licensee at a time mutually agreed to by the parties and will have no obligation to update the Technology at any later period.

License Property
U.S. Patent 8,486,421, entitled “Antigen-Norovirus P-Domain Monomers and Dimers, Antigen-Norovirus P-Particle Molecules, and Methods of Their Making and Use”, filed on Jan. 9, 2010, issued on Jul. 16, 2013, with priority dates of Jun. 9, 2009 (Provisional application No. 61/185.564) and Jul. 10, 2009 (provisional application No. 61/224,696)

U.S. Patent 9,096,644, entitled “Antigen-Norovirus P-Domain Monomers and Dimers, Antigen-Norovirus P-Particle Molecules, and Methods of Their Making and Use”, filed on Jun. 9, 2009, with a priority date of Jul. 10, 2009.

US Patent No 9,562,077, entitled “Protein Complex System for Increased Immunogenicity and Functionality, and Methods Making and Use”, filed on Mar. 14, 2013, with priority date July 11, 2012 (Provisional Application No. 61/670,288).

Field of Use
Field of Use means utilizing the Patents and Technology for all uses other than the Excluded Field relating in general to vaccines, antiviral drugs, drug delivery systems, and vaccine development, and in particular to methods of preparing very large protein complexes for use as a multivalent vaccine for infections caused by virus types.

IPSCIO Record ID: 308732

License Grant
The College grants to Licensee an exclusive, worldwide license, under the Patent Rights solely (a) to identify, discover, develop, make, have made, use, market, offer for sale, sell, have sold and import Type I and Type II Licensed Products and (b) to perform Licensed Services.

The College grants to Licensee a non-exclusive, worldwide, license under its rights in and to the College Technology Transfer Materials solely for use in identifying, discovering, developing, making, having made, using, marketing, offering for sale, selling, having sold and importing any Type I Licensed Product or Type II Licensed Product.

License Property
The College has patent rights covering certain chlamydia antigens.

Type I Licensed Product shall mean any product, the manufacture, use, sale, marketing or importation of which falls within the scope of a Valid Claim in the country in which it is manufactured, used, sold, marketed or imported.  Type II Licensed Product' shall mean any product that is not a Type I Licensed Product, but is identified or discovered through the use of a Licensed Method.

Licensed Services shall mean any service provided for or on behalf of a third party on a fee-for-service basis that entails the practice of a Licensed Method.

Materials transferred include
– Chlamydia libraries (donor library and expression library with and without cLLO)
– pDEST-SL8 expression vector
– Plasmids and E. Coli Strains
– T cell Lines
– Other Cell Lines, and,
– Protocols as follows
1. Gateway cloning
2. CE6 phage prep
3. Library induction
4. Library screening
5. Chlamydia growth and prep
6. T cell expansion (multiple protocols)
7. APC preps
8. Chlamydia infection ( cell line and mouse)
9. B3Z assay for library validation
10. ICS assay for antigen presentation

Field of Use
The field of use is for development of the first such chlamydia vaccine.  The patent families cover chlamydia vaccine and immunogenic compositions and methods for inhibiting or treating chlamydia infections.

Chlamydia, or more specifically a chlamydia infection, is a sexually transmitted infection caused by the bacterium Chlamydia trachomatis.

Licensee is a clinical stage biotechnology company that discovers and develops novel vaccines to address infectious diseases for which no vaccine or vaccines with limited effectiveness exist today.

IPSCIO Record ID: 263928

License Grant
With this amendment, the Parties revise and amend the Agreement to add the Collaboration Compound known as GI-6300 as a Drug Candidate under the Agreement and to remove the Collaboration Compound known as GI-10000 as a Drug Candidate under the Agreement.
License Property
GI-6300 means the series of Tarmogen products that express brachyury. GI-6301 is part of the GI-6300 series and means the single Tarmogen product that may become the subject of [an IND filing under CRADA #02264] and that expresses a human brachyury protein.
Field of Use
The focus of the compound in this agreement is for the treatment of cancer.

IPSCIO Record ID: 307944

License Grant
Under the Collobaration Agreement, Licensor will make the Ii-Key Peptide vaccine technology available to the Chinese Licensees. The Chinese parties will provide facilities and personnel for the development of the COVID-19 vaccine under Licensor technical guidance. The development will include synthesis, analysis and human trials through Phase III, if warranted, in China. The Chinese parties will have exclusive rights to use and commercialize the COVID-19 technology and products in China.
License Property
The licensed property is Ii-Key Peptide vaccine technology.  Ii-Key is a technology that activates the immune response for the treatment of cancer and infectious diseases.
Field of Use
The field of use is to develop a COVID-19 vaccine.  The COVID-19 pandemic has opened significant opportunities to resurrect infectious disease vaccine platform Ii-Key Peptide vaccine technology.  COVID-19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Licensee is an affiliate of the China Technology Exchange, and is enabling the development of the COVID-19 vaccine in China.

IPSCIO Record ID: 230788

License Grant
Licensor grants an exclusive license in the Territory, including the right to grant sublicenses, to manufacture, use, sell, offer for sale, and import Products under all its right, title and interest in the Patent Rights.
License Property
Product means any animal vaccine or therapeutic agent the manufacture, use, sale, offer for sale or import of which would infringe any Valid Claim within Patent Rights in the absence of a license.

Food Safety Product means a Product to eliminate or reduce organisms associated with food borne disease in livestock.

The licensed property include patents for Immunogenic compositions comprising avirulent derivatives of Salmonella typhi with mutations in cya, crp and cdt, Method of maintaining a desired recombinant gene in a genetic population of cells, Avirulent Salmonella containing genes encoding gamete specific antigen useful as vaccine for diminishing or preventing fertility, Method of vaccination of newly hatched poultry, Recombinant vaccines comprising immunogenic attenuated bacteria having RpoS  phenotype, Methods of producing and using virulence attenuated poxRmutant bacteria, Recombinant bacterial system with environmentally limited viability, Live attenuated Salmonella vaccines to control avian pathogens, Regulated Antigen Delivery Systems, and, various patents for Avirulent microbes.

Field of Use
The field of use Area means research, development and commercialization with respect to animal vaccines and therapeutic agent as further described in the Research Plan.

IPSCIO Record ID: 306663

License Grant
The Licensee entered into a worldwide nonexclusive License Agreement with the Licensor, the primary agency of the United States government responsible for biomedical and public health research, for the use of certain patents and tangible materials to be used in the development and commercialization of a vaccine for the SARS-CoV-2 virus.
License Property
The focus is on the development of a vaccine for the SARS-CoV-2 virus and other strains of coronavirus using patented and patent-pending technology.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 is the strain of coronavirus that causes coronavirus disease 2019 (COVID-19), the respiratory illness responsible for the COVID-19 pandemic.

Field of Use
Licensee focus is on developing novel antibiotics against infectious diseases; especially a vaccine for the SARS-CoV-2 virus and other strains of coronavirus using patented and patent-pending technology. The goal is accelerating the development of much needed new antibiotics that can work against resistant strains of bacteria and the development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus.

IPSCIO Record ID: 279292

License Grant
For the Licensed Intellectual Property, Licensor grants the exclusive, even as to Licensor, a worldwide, nontransferable right and license, with the right to grant sublicenses, under the Licensed Intellectual Property, to use, have used, sell, have sold, offer to sell, import, have imported, make and have made, and otherwise research, Develop, Commercialize or manufacture any Licensed Vaccine and/or Licensed Product, during the Term, in the Territory in the Field.

For the Trademarks for Licensed Products. To the extent that Licensor owns any Trademark(s) that pertain specifically to a Licensed Vaccine or Licensed Product, Licensor grants an exclusive right and license, with the right to grant sublicenses to Trademark(s) Controlled by Licensor solely for use with respect to such Licensed Vaccine or Licensed Product, as the case may be.

License Property
Licensor has expertise in drug discovery, development, and manufacturing of yeast-based immunotherapeutics known as Tarmogen® products.

Licensor has rights under certain patent rights and know-how rights relating to Tarmogens.

Licensed Product means any product in final form that contains a Licensed Vaccine as a therapeutically or prophylactically active ingredient.

Combination Product means any product sold in a particular country that contains a Licensed Vaccine in combination with one (1) or more other therapeutically active ingredients or drug delivery technology, devices, equipment or other components, as applicable, or formulated or packaged separately but sold together for a single price.

Field of Use
The collaboration is for the prevention and/or treatment of hepatitis B virus infection and its sequelae.  The goal of the research collaboration is to create and develop therapeutic vaccine products that have specific HBV DNA antigens cloned into S. cerevisiae (a species of yeast).

The Field means, any and all human diseases and conditions, except the treatment of any malignancy; provided, however, that Field shall include [the treatment, palliation, diagnosis and/or prevention of hepatitis that may result in the prevention and/or reduction in frequency and incidence of any and all sequelae of hepatitis infection, including the prevention and/or reduction in the frequency and incidence of hepatocellular carcinoma in patients who have co-existing hepatocellular carcinoma.

IPSCIO Record ID: 371191

License Grant
The Company holds an exclusive, worldwide license from the Licensor, a British university technology transfer and consultancy company, to certain specified patent rights and biological materials relating to the use of epitopes of limited variability and virus-like particle products and practice processes that are covered by the licensed patent rights and biological materials for the purpose of developing and commercializing a vaccine product candidate for influenza. The Company is obligated to use its best efforts to develop and market Licensed Products in accordance with its development plan.
License Property
The patent, United States Patent No. 11,123,442, includes claims directed to specific compositions of polypeptides, or epitopes of limited variability, and methods of treating influenza infection with the compositions.

Epitopes or protein of antigens which can be utilized to develop singular or multi-targeted vaccines. Epitopes can simply be fused to the end of the S domain via flexible linker through recombinant DNA technology.  Identified epitopes of limited variability in H1 influenza that have circulated throughout history (since 1918) and make ideal vaccine targets and have completed similar analysis of H3 and Flu B strains for similar epitopes which will be used to produce our lead vaccine candidate BWV-101 as a universal vaccine for influenza infection.   Due to the cross-reactive nature of the H1 epitopes in pre-pandemic H1 influenza A, companies are pursuing the development of a stand-alone H1 vaccine (BWV-102). These epitopes are able to be formulated into a vaccine candidate using the VLP platform technologies and may be evaluated using other vaccine technologies through partnerships in order to accelerate development of potential vaccines or to explore adjunct therapies.

Field of Use
The Company is currently developing a universal influenza vaccine and an H1N1 vaccine candidate that both utilize the epitopes of limited variability that are covered in the patent.

Field of use is for the treatment of influenza.

IPSCIO Record ID: 308731

License Grant
The Parties now desire to modify their arrangements under the Original Agreement. The Parties agree that the Original Agreement shall be of no further force or effect from and after the Effective Date.

Licensor, a non-profit health care organization, grants to Licensee, under Licensors one-half ownership interest in the Patent Rights, subject to the rights granted under a separate Party License, the worldwide right and exclusive license, with the right to sublicense, to import. make, have made, use, lease, offer for sale, sell and otherwise export the Licensed Products, and to practice the Licensed Processes, in the Territory for the Field of Use during the Term, unless sooner terminated as provided in this Agreement.

License Property
Licensor is involved in research for the field of pneumococcal T cell-based protein vaccines. This research project relates to Novel high-throughput screening platform to develop a pneumococcal protein-based vaccine.

The patent applications include 61/221,541; 61/240,616; 61/316,267; 12/826,084; 61/434,818; 13/355,468; 61/589,267; and, 61/609,171.

Field of Use
Field of use shall mean the prevention and treatment of Streptococcus pneumoniae.

Streptococcus pneumoniae (pneumococcus) is a Gram-positive bacterium that is responsible for the majority of community-acquired pneumonia. It is a commensal organism in the human respiratory tract, meaning that it benefits from the human body, without harming it

Licensee has rights to Patt Vaccine Sustems that include a non-exclusive right to sublicense, to develop, make or have made, and use a pneumococcal T cell based protein vaccine in the world and (ii) use market, promote, distribute and sell a pneumococcal T cell-based protein vaccine in Developing Countries.

Licensee has developed and/or controls a high-throughput system for in vitro screening of proven effectors of immunity ( e.g. libraries of efficacious T cells) to identify their specific target antigens from the complete proteome of any disease-causing agent, the High Throughput System.  It has determined that a whole cell vaccine (WCV) made from killed unencapsulated pncumococcal cells, as well as purified antigens, can protect animals against colonization via CD4 + T Hl7 responses.

IPSCIO Record ID: 336296

License Grant
Licensor hereby grants to United Kingdom Licensee and its Affiliates an exclusive, royalty-bearing license throughout the Territory, with the right to grant sublicenses in accordance with the terms of this Agreement, under Licensors interest in the Licensor Patents, Licensor Technology and Joint Inventions, to develop, register, use, make, have made, import, export, offer to sell, sell and have sold HPV Vaccines and/or Antigens and/or Process.  Licensee agrees that it will use Licensor Technology and Licensor Patents only as licensed under this Agreement.
License Property
HPV Vaccine shall mean a vaccine for the prevention, control or treatment of human papilloma virus infection in humans in any formulation, configuration or delivery system or a product or process for the diagnosis of HPV infection in humans.

Antigen shall mean (i) HPV antigens and/or (ii) HPV proteins and/or (iii) other physical forms based on such antigens, such as peptides and/or nucleic acid(s) (DNA, RNA) delivered in any form including recombinant vectors.

Vaccine Product shall mean an HPV Vaccine (x)covered in whole or in part by a Licensor Patent or an Licensee Patent which covers Licensee Special Technology and/or (y) which incorporates or is derived from the use of Licensor Technology and/or Licensee Special Technology.  

Licensor Patents shall mean
5,298,418 – Cell line isolated from larval midgut tissue of Trichoplusia ni
5,300,435 – Trichoplusia ni cell line which supports replication of baculoviruses
5,437,951 – Self-assembling recombinant papillomavirus capsid proteins

Licensor Technology shall mean information, know-how and materials, including, but not limited to, pharmaceutical, chemical and biological products, technical and non-technical data and information (i) owned by Licensor and/or to which Licensor has a transferable interest on the Effective Date and/or at any time during the term of this Agreement and (ii) which relate to the field of L1 based HPV Vaccines and/or which arise from the Research Program, and in each case which are necessary or useful for the development, manufacture, use or sale of an HPV Vaccine.

Field of Use
Field of use is for the treatment for the human papilloma virus (AHPV@) (HPV).

Human papillomavirus (HPV) is the most common sexually transmitted infection (STI).
Many people with HPV don't develop any symptoms but can still infect others through sexual contact. Symptoms may include warts on the genitals or surrounding skin.
There's no cure for the virus and warts may go away on their own. Treatment focuses on removing the warts. A vaccine that prevents the HPV strains most likely to cause genital warts and cervical cancer is recommended for boys and girls.

IPSCIO Record ID: 345562

License Grant
English Licensor granted a nonexclusive license to Licensee to produce and characterize potential product candidates using the Company’s viral vector technology and to provide research services to Licensee during the research term which commenced on June 2019 through the end of 66 months and for up to six vaccine products based on antigens discovered via Licensee’s proprietary platform.
License Property
Viral vector technology is known as ChAdOx1 and ChAdOx2.  This platform comprises several components that, when combined, allow the developed product candidates designed to induce high and durable levels of antigen-specific T cells and B cells, to prevent and treat infectious diseases and cancer.

ChAdOx1 and ChAdOx2 are modified simian adenoviral vectors which deliver target antigens into cells to generate a specific immune response. These viruses were originally isolated from chimpanzees to avoid pre-existing immunity issues affecting the use of human adenovirus vectors.

Field of Use
Field of use is for the immunotherapy and vaccine fields.

IPSCIO Record ID: 328343

License Grant
Licensor grants to Licensee an exclusive license under Licensor know-how and Licensor Patent Rights to develop, make, have made, use and sell Licensed Products in the territory with the right to grant sublicenses to affiliates of Licensee and those persons or entities through whom Licensee,  in the normal course of its business collaborates in the manufacture and sale of its products; provided, however, that nothing in this Agreement shall prohibit Licensor from utilizing the Licensor know-how and/or Licensor Patent Rights, exclusive of Licensee Know-how, to develop, make, have made, use and sell, either by itself or with one or more third  parties, products for the treatment of human infectious diseases.
License Property
Technology pertaining to the intramuscular delivery of vaccines for the prevention of human infectious disease that consist of DNA and/or RNA gene sequences derived from the genome of the infectious agent which would prevent clinical disease from an infection.

AIDS Vaccine means a vaccine which would prevent an infection by Human Immunodeficiency Virus (HIV-1) and/or clinical diseases caused by infection with HIV-1 in humans.

Influenza Vaccine means a vaccine which would prevent an infection and/or significant clinical diseases caused by any influenza virus in humans.

Licensed Product means a bulk or finished AIDS Vaccine or Influenza Vaccine, or other vaccine for the prevention of human infectious disease if licensed hereunder, which utilizes the Technology or technology which is developed by Licensor during and as a result of the Research Collaboration Program; provided, however, that if any such vaccine is also capable of being used for treatment of the same human infectious disease, then such therapeutic use of such vaccine shall also be considered a Licensed Product for purposes of the license being granted by Licensor to Licensee under this Agreement.

Field of Use
Field of Use is for the prevention of human infectious disease.

IPSCIO Record ID: 257474

License Grant
The original agreement is an exclusive license under Licensor patent rights and know-how to develop, make, have made, use and sell Licensed products in the Territory.
License Property
With this amendment, Licensed products shall also mean Treatment vaccines.  Treatment vaccines shall mean a bulk or finished vaccine.

The parties wish to further amend the Agreement to provide that Merck shall have rights to vaccine products for the treatment of patients infected with Human Immunodeficiency Virus and Hepatitis B Virus.

Field of Use
The field of use is for the treatment of Human Immunodeficiency Virus (HIV-1) and/or diseases caused by infection with HIV-I in humans and Hepatitis B Virus (HBV) and/or diseases caused by infection with HBV in humans, which utilizes the Technology or technology which is developed by Licensor during and as a result of the Research Collaboration Program.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.